{"id":72264,"date":"2026-08-11T12:43:29","date_gmt":"2026-08-11T04:43:29","guid":{"rendered":"https:\/\/flcube.com\/?p=72264"},"modified":"2026-08-11T12:43:30","modified_gmt":"2026-08-11T04:43:30","slug":"beone-medicines-and-revolution-medicines-announce-clinical-collaboration-and-regional-licensing-deal-on-rason-inhibitors-across-select-asian-markets","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72264","title":{"rendered":"BeOne Medicines and Revolution Medicines Announce Clinical Collaboration and Regional Licensing Deal on RAS(ON) Inhibitors Across Select Asian Markets"},"content":{"rendered":"\n

BeOne Medicines Ltd. (NASDAQ: ONC<\/a>; HKG: 6160<\/a>; SHA: 688235<\/a>)<\/strong> announced a multifaceted collaboration agreement<\/strong> with Revolution Medicines, Inc. (NASDAQ: RVMD<\/a>)<\/strong>, combining a clinical collaboration<\/strong> to evaluate combinations of select BeOne clinical\u2011stage oncology candidates with Revolution Medicines’ four clinical\u2011stage RAS(ON) inhibitors<\/strong>, and a regional licensing agreement<\/strong> granting BeOne exclusive rights in select Asian markets.<\/p>\n\n\n\n

Deal Overview<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Parties<\/strong><\/td>BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) \u00d7 Revolution Medicines, Inc. (NASDAQ: RVMD)<\/td><\/tr>
Deal Type<\/strong><\/td>Multifaceted collaboration: clinical collaboration + regional licensing<\/td><\/tr>
Clinical Scope<\/strong><\/td>Combinations of select BeOne clinical\u2011stage oncology candidates with any one or more of Revolution Medicines’ four clinical\u2011stage RAS(ON) inhibitors<\/td><\/tr>
Licensing Scope<\/strong><\/td>Exclusive development and\/or commercialization rights to the four RAS(ON) inhibitors in select Asian markets<\/td><\/tr>
Announcement Date<\/strong><\/td>10 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Revolution Medicines’ RAS(ON) Inhibitor Portfolio<\/h2>\n\n\n\n
Candidate<\/th>Selectivity<\/th>Stage<\/th><\/tr><\/thead>
Daraxonrasib<\/strong><\/td>RAS(ON) multi\u2011selective inhibitor<\/td>Clinical stage<\/td><\/tr>
Zoldonrasib<\/strong><\/td>RAS(ON) G12D\u2011selective inhibitor<\/td>Clinical stage<\/td><\/tr>
Elironrasib<\/strong><\/td>RAS(ON) G12C\u2011selective inhibitor<\/td>Clinical stage<\/td><\/tr>
RMC\u20115127<\/strong><\/td>RAS(ON) G12V\u2011selective inhibitor<\/td>Clinical stage<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Collaboration \u2013 Planned Combination Studies<\/h2>\n\n\n\n

The parties will evaluate and advance combination therapies pairing specific BeOne candidates with Revolution Medicines’ RAS(ON) inhibitors:<\/p>\n\n\n\n

BeOne Candidate<\/th>Modality<\/th>Planned Combination Partner<\/th><\/tr><\/thead>
BGB\u201158067<\/strong><\/td>MTA\u2011cooperative PRMT5 inhibitor<\/td>Daraxonrasib or zoldonrasib<\/td><\/tr>
BG\u2011T187<\/strong><\/td>EGFR\u00d7MET\u00d7MET trispecific antibody<\/td>Daraxonrasib or zoldonrasib<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Regional Licensing Agreement \u2013 Financial and Territorial Terms<\/h2>\n\n\n\n
Component<\/th>Detail<\/th><\/tr><\/thead>
Licensed Assets<\/strong><\/td>Four clinical\u2011stage RAS(ON) inhibitors: daraxonrasib, zoldonrasib, elironrasib, RMC\u20115127<\/td><\/tr>
Licensed Territory<\/strong><\/td>Select Asian markets<\/td><\/tr>
Rights Granted to BeOne<\/strong><\/td>Exclusive development and commercialization rights \u2014 or exclusive commercialization rights, depending on the market<\/td><\/tr>
Compensation to Revolution Medicines<\/strong><\/td>Development and sales milestone payments + tiered royalties on net sales in the licensed territory<\/td><\/tr>
Rights Retained by Revolution Medicines<\/strong><\/td>Full development and commercialization rights outside the licensed territory, including Japan and South Korea<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

BeOne to Fund Global Registrational Phase 3 Study<\/h2>\n\n\n\n

As part of the collaboration, BeOne<\/strong> will leverage its differentiated, fully internal clinical development capability<\/strong> to fund and conduct a global registrational Phase 3 clinical study<\/strong> for one of Revolution Medicines’ RAS(ON) inhibitors. Concurrently, Revolution Medicines continues to advance multiple global registrational studies<\/strong> across its portfolio.<\/p>\n\n\n\n

Strategic Rationale & Market Impact<\/h2>\n\n\n\n